← Back to Search

Other

Gabapentin for Spinal Cord Injury Neurorecovery

Phase 4
Recruiting
Led By Dr. Kimberly Anderson, PhD
Research Sponsored by MetroHealth Medical Center
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Traumatic SCI
Age 18 years and older
Timeline
Screening 3 weeks
Treatment Varies
Follow Up across 6 month study duration per participant
Awards & highlights

Study Summary

This trial will test whether gabapentin can help with neurorecovery, and whether it is feasible to conduct a well-designed study on the efficacy of the intervention in the future.

Who is the study for?
This trial is for adults who have experienced a traumatic spinal cord injury (SCI) of any level or severity, and can start the study drug within 120 hours after their injury. They must be able to understand and agree to participate in the trial. People with moderate/severe brain injuries or those already using gabapentinoids at the time of injury cannot join.Check my eligibility
What is being tested?
The study is testing whether taking Gabapentin early on can help with nerve recovery after a spinal cord injury. Participants will either receive Gabapentin or a placebo, which has no active ingredients, to see if there's a difference in recovery outcomes.See study design
What are the potential side effects?
While not specified here, common side effects of Gabapentin may include dizziness, fatigue, and coordination problems. The placebo group should not experience medication-related side effects since it contains no active drug.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I have a spinal cord injury due to trauma.
Select...
I am 18 years old or older.
Select...
My spinal cord injury ranges from complete to incomplete.
Select...
I understand the information given to me and can communicate my decision.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~across 6 month study duration per participant
This trial's timeline: 3 weeks for screening, Varies for treatment, and across 6 month study duration per participant for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Treatment Protocols
Number of occurrences of unblinding
Number of participants recruited
+1 more

Side effects data

From 2021 Phase 4 trial • 88 Patients • NCT03012815
2%
Allergic reaction
100%
80%
60%
40%
20%
0%
Study treatment Arm
Gabapentin
Benzodiazepine

Trial Design

3Treatment groups
Experimental Treatment
Placebo Group
Group I: Medium doseExperimental Treatment1 Intervention
1800 mg treatment groups will receive 2 capsules of gabapentin by mouth 3 times per day for 90 days.
Group II: Low doseExperimental Treatment1 Intervention
600mg treatment group will receive 2 capsules of gabapentin by mouth 3 times per day for 90 days.
Group III: ControlPlacebo Group1 Intervention
The control group will receive 2 placebo capsules of inert cellulose by mouth 3 times per day for 90 days.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Gabapentin
FDA approved

Find a Location

Who is running the clinical trial?

MetroHealth Medical CenterLead Sponsor
114 Previous Clinical Trials
21,347 Total Patients Enrolled
National Institute on Disability, Independent Living, and Rehabilitation ResearchFED
71 Previous Clinical Trials
9,087 Total Patients Enrolled
Dr. Kimberly Anderson, PhDPrincipal InvestigatorMetrohealth Medical Center-Case Western Reserve University School of Medicine

Media Library

Gabapentin (Other) Clinical Trial Eligibility Overview. Trial Name: NCT05302999 — Phase 4
Spinal Cord Injury Research Study Groups: Low dose, Medium dose, Control
Spinal Cord Injury Clinical Trial 2023: Gabapentin Highlights & Side Effects. Trial Name: NCT05302999 — Phase 4
Gabapentin (Other) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05302999 — Phase 4

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

How many individuals is the study limited to in its current iteration?

"Yes, the information on clinicaltrials.gov states that this ongoing medical trial is inviting potential candidates to join in their research initiative. This study was first posted on March 14th 2022 and its most recent update took place on March 29th 2022. Currently, 42 patients are being recruited at one site for this project."

Answered by AI

Has Gabapentin been given the greenlight by the FDA?

"Gabapentin's safety has been affirmed through Phase 4 trials, thus it was given a rating of 3."

Answered by AI

Are there any vacancies in this trial for interested participants?

"Per the records published on clinicaltrials.gov, candidates are being sought to participate in this study which was originally posted March 14th and recently amended on 29th of same month."

Answered by AI

Who else is applying?

How old are they?
18 - 65
What portion of applicants met pre-screening criteria?
Did not meet criteria
Recent research and studies
clinicaltrials.govStudy
Feasibility of Early Gabapentin as an Intervention for Neurorecovery
Kimberly Anderson, PhD 2022. "Feasibility of Early Gabapentin as an Intervention for Neurorecovery". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT05302999.
All > Spinal Cord Injury > Gabapentin
~22 spots leftby Aug 2026
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top